Results 121 to 130 of about 26,548 (293)

Current state of knowledge about spironolactone-induded gynecomastia. Review 2024

Quality in Sport
Spironolactone, a potassium-sparing diuretic, acts as an aldosterone antagonist but also has anti-androgen properties, leading to increased estrogen levels in the body. It can cause gynecomastia in men by blocking the production of androgens, preventing
Oliwia Kamila Iszczuk, Julia Silldorff, Tomasz Fura, Marcin Dudek, Radosław Zaucha, Magdalena Gajkiewicz, Zuzanna Felińska, Małgorzata Zając, Stanisław Anczyk   +8 more
doaj   +1 more source

Recovery of complete left bundle branch block in dilated cardiomyopathy after optimal heart failure treatment: a case report [PDF]

Journal of Medicine and Life Science
Complete left bundle branch block (CLBBB) is a significant cardiac conduction abnormality often associated with dilated cardiomyopathy (DCM). This case report highlights the improvement in CLBBB and symptom relief through reverse cardiac remodeling in a ...
Geum Ko, Jae-Geun Lee
doaj   +1 more source

Rapid and MR-Independent IK1 activation by aldosterone during ischemia-reperfusion [PDF]

, 2015
In ST elevation myocardial infarction (STEMI) context, clinical studies have shown the deleterious effect of high aldosterone levels on ventricular arrhythmia occurrence and cardiac mortality.
Alexandre, J, Beygui, F, Guinamard, R, Hof, T, Manrique, A, Milliez, P., Puddu, Paolo Emilio, Rouet, R, Sallé, L   +8 more
core   +3 more sources

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists

Vascular Health and Risk Management, 2017
Mineralocorticoid-receptor antagonists (MRAs) have proven to be effective in some types of hypertension, especially in resistant hypertension (RHTN). In this phenotype of hypertension, the renin-angiotensin-aldosterone pathway plays an important role, with MRAs being especially effective in reducing blood pressure. In this review, we show the relevance
Juan Carlos Yugar-Toledo, Rodrigo Modolo, Ana Paula de Faria, Heitor Moreno   +3 more
openaire   +4 more sources

Prognostic impact of iron deficiency in new‐onset chronic heart failure: Danish Heart Failure Registry insights

ESC Heart Failure, Volume 12, Issue 2, Page 1346-1357, April 2025.
Abstract Aims Iron deficiency (ID) is prevalent in chronic heart failure (HF) but lacks a consensus definition. This study evaluates the prevalence and the prognostic impact of ID using different criteria on all‐cause and cardiovascular mortality, as well as first hospitalization for HF in patients with new‐onset chronic HF.
Abdullahi Ahmed Mohamed, Daniel Mølager Christensen, Milan Mohammad, Christian Torp‐Pedersen, Lars Køber, Emil Loldrup Fosbøl, Tor Biering‐Sørensen, Morten Lock Hansen, Mariam Elmegaard Malik, Nina Nouhravesh, Charlotte Anderrson, Morten Schou, Gunnar Gislason   +12 more
wiley   +1 more source

A Delphi consensus project to capture experts' opinion on hyperkalaemia management across the cardiorenal spectrum

ESC Heart Failure, Volume 12, Issue 2, Page 1132-1140, April 2025.
Abstract The main purpose of this project was to capture experts' opinion on hyperkalaemia management and form best practice recommendations for cardiorenal patients in Greece. A steering committee of nephrologists and cardiologists developed 37 statements. An online questionnaire completed by 32 experts in cardiorenal management in Greece.
Christina Chrysohoou, Maria Marketou, Maria Aktsiali, Ioannis Griveas   +3 more
wiley   +1 more source

Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with RAAS-inhibitors - Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. [PDF]

, 2018
Renin angiotensin aldosterone system inhibitors/antagonists/blockers (RAASi) are a cornerstone in treatment of patients with cardiovascular diseases especially in those with heart failure (HF) due to their proven effect on surrogate and hard end-points ...
Acker, Alfonzo, An, Anker, Bakris, Beusekamp, Bozkurt, Chang, Chen, Clausen, Cooper, Desai, Dittrich, Einhorn, Elliott, Epstein, Epstein, Epstein, Eschalier, Ingelfinger, Jain, Kamel, Kayexalate (sodium polystyrene) [package insert], Khanagavi, Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, Kjeldsen, Komajda, Lund, Luo, Maggioni, Mancia, Mathialahan, Mattu, McCullough, Molnar, Montalescot, National Institute for Health and Care Excellence (NICE), Packham, Palmer, Perazella, Pitt, Pitt, Pitt, Pitt, Pitt, Ponikowski, Poole-Wilson, Raebel, Ramadan, Rastegar, Rossignol, Rossignol, Rydén, Sarafidis, Shah, Sterns, Takaichi, Tamargo, Tamargo, UK Renal Association, Vardeny, Vardeny, Wei, Weir, Weir, Weir, Weisberg   +66 more
core   +2 more sources

FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran, Vinay Randhawa, Usman A. Tahir, Matthew Robertson, Anam A. Waheed, Anna Perillo, Leanne Barrett, Ron Blankstein, Mark W. Feinberg, Marcelo F. Di Carli, Neal K. Lakdawala   +10 more
wiley   +1 more source

Effect of Mineralocorticoid receptor antagonism (MRA) on aldosterone-interleukin 6 axis in heart failure; second opinion. A case-control study

The Egyptian Journal of Internal Medicine
Background In cases of heart failure characterized by reduced ejection fraction (HFrEF), heightened levels of aldosterone negatively impact the progression of heart failure.
H. ElSawi, S. Zidan, A. Elborolosy
doaj   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source